Mass drug administration (MDA)
Mass Drug Administration (MDA), defined by WHO as the administration of antimalarial treatment to all age groups of a defined population or every person living in a defined geographical area (except those for whom the medicine is contraindicated) at approximately the same time and often at repeated intervals [ref], has been historically a key component of malaria control and elimination strategies.
In 2015, WHO published recommendations for the use of MDA, mass screening and treatment and focal screening and treatment for malaria [ref]. In the years following the publication of these recommendations and after the release of a practical field manual of MDA for P. falciparum [ref], new studies have been conducted and novel field experience is being acquired. Therefore, WHO convened a meeting to revise and refine the current recommendations for the use of MDA, focusing on its role on decreasing transmission and accelerating progress towards elimination [ref, ref].
With the aim of facilitating the discussions at the Evidence Review Group (ERG) on MDA for malaria held in September 2018 [ref], this deep dive compiles the landscape of recent and ongoing research in antimalarial MDA and provides an overview of the projects’ main characteristics.
Deep dive outputs:
- For the approach MESA used in compiling this deep dive see